Clinical trials: Pituitary Diseases
Acromegaly
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or…
- Trial name
- LEAD (NCT00701363)
- Testing
- Lanreotide Autogel 120 mg
- Where
- 44 sites in Brazil, Denmark and 12 more
- Volunteers
- 124 people
- Sponsor
- Ipsen
Acromegaly
Open Label Study of Octreotide Implant in Patients With Acromegaly
To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) response of a hydrated and non-hydrated 84 mg octreotide implant in patients with acromegaly in the first 6 weeks of treatment.
- Trial name
- NCT00913055
- Testing
- octreotide acetate
- Volunteers
- 34 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acromegaly
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly.
- Trial name
- NCT00225979
- Testing
- Octreotide LAR
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NNC126-0083 in growth hormone deficient adults
- Trial name
- NCT00715689
- Testing
- NNC126-0083
- Where
- 3 sites in Denmark
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Dwarfism, Pituitary
Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®
This is an open-label, prospective, multicentric, non-comparative, non-randomized Phase IV interventional study in which subjects pre-diagnosed with Growth Hormone Deficiency (GHD) were treated for 4 weeks with Saizen to compare…
- Trial name
- NCT01187550
- Testing
- Recombinant human growth hormone (r-hGH)
- Volunteers
- 214 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Adult Growth Hormone Deficiency, Endocrine System Diseases
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly.
- Conditions
- Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Trial name
- NCT05171855
- Testing
- Lonapegsomatropin
- Where
- 85 sites in United States, Armenia and 19 more
- Volunteers
- 220 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Pituitary Tumors
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate…
- Trial name
- NCT01689727
- Testing
- Technetium Tc 99m EC20
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Endocyte
Growth Hormone Deficiency With Pituitary Anomalies
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial.
- Trial name
- NCT02558829
- Testing
- Macimorelin, Insulin
- Where
- 27 sites in United States, Austria and 7 more
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- AEterna Zentaris
Dwarfism, Pituitary
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech GH preparations to treat GH-deficient subjects with optimal GH dosing during puberty.
- Trial name
- NCT00097513
- Where
- United States
- Sponsor
- Genentech, Inc.
Adult Growth Hormone Deficiency
Versartis International Trial in Adults With Long-Acting Growth Hormone
A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.
- Trial name
- VITAL (NCT02526420)
- Testing
- somavaratan
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 36 people
- Sponsor
- Versartis Inc.
Dwarfism, Pituitary
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children
This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad population of children.
- Trial name
- NCT02314676
- Testing
- PEG-somatropin
- Where
- 2 sites in China
- Volunteers
- 900 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Acromegaly
Somatuline Autogel: Acromegaly Self/Partner Injection Study
The purpose of this study is to allow patients with acromegaly, or their partners, to learn how to successfully inject Somatuline Autogel at home.
- Trial name
- NCT00149188
- Testing
- Lanreotide (Autogel formulation)
- Where
- 10 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Ipsen
Acromegaly
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison…
- Trial name
- OXTEND™-03 (NCT06930625)
- Testing
- Debio 4126
- Where
- 74 sites in United States, Austria and 19 more
- Volunteers
- 119 people
- Sponsor
- Debiopharm International SA
Hypopituitarism, Pituitary Insufficiency
A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults
The Hypopituitary Control and Complications Study "HypoCCS" is a prospective, open label, global, multicentre, observational study on routine clinical care of adults with growth hormone deficiency occurring either isolated or in…
- Conditions
- Hypopituitarism, Pituitary Insufficiency, Growth Hormone Deficiency, Adult
- Trial name
- HypoCCS (NCT01088399)
- Testing
- Somatropin (rDNA origin)
- Volunteers
- 10,673 people
- Sponsor
- Eli Lilly and Company
Acromegaly
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.
- Trial name
- SALSA (NCT00447499)
- Testing
- Somatuline Autogel (lanreotide acetate), Home administration
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ipsen
Acromegaly
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
The purpose of this pilot study is to test SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level - IGF-1 - Tumour).
- Trial name
- SAGIT Pilot (NCT02231593)
- Testing
- SAGIT
- Where
- 21 sites in United States, Brazil and 5 more
- Volunteers
- 71 people
- Sponsor
- Ipsen
Cushing's Disease
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.
- Trial name
- LINC-4 (NCT02697734)
- Testing
- osilodrostat
- Where
- 36 sites in United States, Belgium and 12 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Cutivate Lotion HPA Axis Pediatric Study
A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.
- Trial name
- NCT00546000
- Testing
- Fluticasone propionate 0.05% lotion
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
This trial is conducted in Japan. This protocol describes an extension trial to supply hGH to subjects who wish continuous treatment after the long-term Phase 3 trial (GHLiquid-1519) until hGH products have been approved for GHDA…
- Trial name
- NCT00184730
- Testing
- somatropin
- Where
- Japan
- Volunteers
- 86 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency (GHD)
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
This is a Multi-national Trial. The Goal of the Trial is to Offer Subjects Who Complete 12 Months in the LUM-201-10 Phase 3 Trial up to an Additional 36 Months of Treatment of LUM-201 While Evaluating Safety and Tolerability of…
- Trial name
- NCT07129759
- Testing
- LUM-201
- Volunteers
- 150 people
- Sponsor
- Lumos Pharma